<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163001">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01747096</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 11/5-K</org_study_id>
    <nct_id>NCT01747096</nct_id>
  </id_info>
  <brief_title>TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors</brief_title>
  <acronym>68-DOTANOC-GEP</acronym>
  <official_title>Diagnostic, Prospective, Comparative, Multicentric Study of the PET / CT With 68Ga-DOTANOC Versus Conventional Imaging Procedures (octréoscan ® Scintigraphy and CT / MRI) in the Assessment of in Gastroenteropancreatic Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the  diagnostic performance of PET / CT with 68Ga-DOTANOC in
      Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in
      routine clinical practice (octreoscan ®  ; multiphase SPECT / CT, MRI or endoscopy).

      Therapeutic impact and safety of PET / CT with 68Ga-DOTANOC will also be assessed.  Expected
      results are a confirmation of the superiority of 68Ga-PET DOTANOC versus scintigraphy
      octreoscan ®, with a potential impact on the therapeutic management of patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Detection of Gastroenteropancreatic Neuroendocrine Tumors  lesions in the initial assessment or during the search of recurrence.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reference to the gold standard (that will be obtained from the data of histology and / or follow-up imaging at least 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the diagnostic performance of PET / CT with 68Ga-DOTANOC with the standard process</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess the clinical impact of PET / CT 68 Ga-DOTANOC in terms of specificity and predictive value for the detection of locations of GEP.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Assess the relevance of decisions of PET / CT 68 Ga-DOTANOC in terms of specificity and predictive value for the detection of locations of GEP.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Assess  the value of PET / CT 68 Ga-DOTANOC in terms of specificity and predictive value for the detection of locations of GEP.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Tolerance of 68-Ga-DOTANOC</measure>
    <time_frame>12 mois</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the vital signs and clinical  tolerance will be assess during the 2 hours following injection of the radiopharmaceutical.</description>
  </other_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Patients With Gastroenteropancreatic Neuroendocrine Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68-Ga-DOTANOC</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  effective contraception or exclusion of pregnancy dosage of beta-HCG in women of
             childbearing age

          -  Fortuitous discovery of suggestive tumors of TE-GEP with well documented conventional
             imaging (multiphase CT; MRI, US endoscopy) associated or not associated  with
             clinical or biological signs of TE-GEP tumors (increase in tumor markers) OR

          -  Histologically proven GEP-TE (WHO classification 2010 (26) well differentiated in the
             initial staging OR

          -  Suspicion of recurrence or progression of well differentiated TE-GEP tumors on
             conventional imaging or laboratory tests (increase in tumor markers) OR

          -  Clinical or biological syndrome strongly suggestive of digestive endocrine disease
             without identification of lesions with conventional imaging

          -  Informed consent and patient's written

          -  Affiliation to an insurance

        Exclusion Criteria:

          -  Multiple endocrine neoplasia

          -  TE GEP tumor not differentiated

          -  Pregnancy and lactation

          -  Persons protected by law

          -  Restlessness, inability to lie still hold at least 1 hour; Claustrophobia

          -  Poor compliance predictable or inability to undergo medical test for geographical,
             social or psychological

          -  Treatment with radiotherapy, chemotherapy or other antitumor treatment within 6 weeks
             of previous morphological and scintigraphic examinations. In case of treatment with
             somatostatin analogues delayed, scans will be performed 4 weeks after the last
             injection. However, a shorter period may be observed to avoid to do again the initial
             assessment exams.

          -  malignancy except basal cell cancers and cancer in situ of the cervix

          -  Contraindication of  injection of a contrast agent necessary for the production of
             multiphase scanner.

          -  Patients who had a CT scan without injection of contrast material can not participate
             in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Ansquer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Ansquer, MD</last_name>
    <phone>0032 2 40 08 4136</phone>
    <email>catherine.ansquer@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evelyne Scotet-Cérato, PhD</last_name>
    <phone>00 32 253482840</phone>
    <email>evelyne.cerato@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Angers Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliiver Couturier, PhD, MD</last_name>
      <email>Olivier Couturier &lt;ocouturier70@me.com&gt;</email>
    </contact>
    <contact_backup>
      <last_name>Evelyne Scotet-Cérato, PhD</last_name>
      <phone>0032253482840</phone>
      <email>evelyne.cerato@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier Couturier, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Rohmer, PU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitutut de Cancérologie de l'Ouest, René Papin</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Morel, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Evelyne Scotet-Cérato, PhD</last_name>
      <phone>0032253482840</phone>
      <email>evelyne.cerato@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Oliver Morel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evelyne Scotet-Cérato, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Rachida Labtahi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evelyne Scotet-Cérato, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique Leguludec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest, René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Rousseau, PhD, MD</last_name>
      <phone>0032240679931</phone>
      <email>Rousseau Caroline &lt;Caroline.Rousseau@ico.unicancer.fr&gt;</email>
    </contact>
    <contact_backup>
      <last_name>Evelyne Scotet-Cérato, PhD</last_name>
      <phone>0032253482840</phone>
      <email>evelyne.cerato@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Caroline Rousseau, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes Hospital</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Ansquer, MD</last_name>
      <phone>0032240084136</phone>
      <email>catherine.ansquer@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Evelyne Scotet-Cérato, PhD,</last_name>
      <phone>0032253482840</phone>
      <email>evelyne.cerato@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine Ansquer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>November 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroenteropancreatic Neuroendocrine Tumors</keyword>
  <keyword>immuno PET (iPET)</keyword>
  <keyword>Gallium (68-Ga)</keyword>
  <keyword>DOTANOC</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
